Quoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin Syndrome

Quoin Pharmaceuticals received FDA Fast Track Designation for QRX003 as a treatment for Peeling Skin Syndrome. The designation can accelerate regulatory interactions and development for the rare-disease therapy, representing a meaningful positive catalyst for QNRX.